Overview

High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial

Status:
Completed
Trial end date:
2022-01-31
Target enrollment:
0
Participant gender:
All
Summary
High-Dose Vitamin D3 in the Treatment of Human Immune Deficiency Virus Patients, A Double-Blind Randomized Control Trial Human immunodeficiency virus is a key challenge for global health. Vitamin D deficiency is common in people living with HIV infection. Antiretroviral therapy may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of the Punjab
Collaborator:
The National HIV/AIDS Programme
Treatments:
Calcifediol
Hydroxycholecalciferols
Criteria
Inclusion Criteria:

1. Age from 19 years and above

2. Vitamin-D levels less than 20ng/ml

3. Not taking any kind of Vitamin-D supplementation or Mega Doses for last six months

4. Written Informed Consent Form

5. PCR Positive Patients

Exclusion Criteria:

1. Pregnant and Lactating Women

2. Ability to take Study Medication Orally